The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.
Mark R Litzow; Megan Othus; Larry D Cripe; Steven D Gore; Hillard M Lazarus; Sandra J Lee; John M Bennett; Elisabeth M Paietta; Gordon W Dewald; Jacob M Rowe; et al. (Profiled Author: Steven Gore)
Mayo Clinic, Rochester, MN 55905, USA. firstname.lastname@example.org
British journal of haematology 2010;148(2):217-25.
The treatment of relapsed acute myeloid leukaemia (AML) remains unsatisfactory. We conducted a phase II randomized trial where patients received intermediate-dose cytarabine for 4 d followed by gemtuzumab ozogamicin on day 5 (Arm A), or combined with liposomal daunorubicin for 3 d (Arm B), or cytarabine given for 5 d combined with cyclophosphamide for 3 d and topotecan by continuous infusion for 5 d (Arm C). Eligible patients had primary refractory AML, a first relapse after a remission of <1 year, or a second or greater relapse. The primary objective of this trial was attainment of a conventional complete remission (CR) or a CR without platelet recovery (CRp) in at least 40% of patients. The CR/CRp rates for the 82 eligible patients were 3/26 (12%) in Arm A, 2/29 (7%) in Arm B, and 1/27 (4%) in Arm C. No patients who had relapsed within 6 months of initial CR or who had suffered multiple relapses responded. More than 95% of patients subsequently died of AML. No unexpected toxicities were encountered. We conclude that none of these three regimens were effective enough in the treatment of high-risk relapsed or refractory AML to warrant further study. This trial was registered at http://www.clinicaltrials.gov as #NCT00005962.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Todd M Cooper; Janet Franklin; Robert B Gerbing; Todd A Alonzo; Craig Hurwitz; Susana C Raimondi; Betsy Hirsch; Franklin O Smith; Prasad Mathew; Robert J Arceci; et al.Cancer 2012;118(3):761-9.
Judith KarpClinical advances in hematology & oncology : H&O 2008;6(11):8-10.
Todd L Rosenblat; Michael R McDevitt; Deborah A Mulford; Neeta Pandit-Taskar; Chaitanya R Divgi; Katherine S Panageas; Mark L Heaney; Suzanne Chanel; Alfred Morgenstern; George Sgouros; et al.Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(21):5303-11.
Appears in this Publication
Author of this Publication